

Eligible references

1. Attias P, Sakhi H, Rieu P, Soorkia A, Assayag D, Bouhroum S, Nizard P, El Karoui K. Antibody response to BNT162b2 vaccine in maintenance hemodialysis patients. *Kidney International* 2021, doi:10.1016/j.kint.2021.04.009.
2. Billany RE, Selvaskandan H, Adenwalla SF, Hull K, March DS, Burton JO, Bishop NC, Carr EJ, Beale R, Tang JW, et al. Seroprevalence of antibody to S1 spike protein following vaccination against COVID-19 in patients on haemodialysis. A call to arms. *Kidney International* 2021, doi:10.1016/j.kint.2021.04.008.
3. Goupil R, Benlarbi M, Beaubien-Souligny W, Nadeau-Fredette A-C, Chatterjee D, Goyette G, Lamarche C, Tom A, Finzi A, Suri RS. Short-term antibody response and tolerability of one dose of BNT162b2 vaccine in patients receiving hemodialysis. *medRxiv* 2021:2021.2003.2030.21254652, doi:10.1101/2021.03.30.21254652.
4. Kennedy NA, Lin S, Goodhand JR, Chanchlani N, Hamilton B, Bewshea C, Nice R, Chee D, Cummings JRF, Fraser A, et al. Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD. *Gut (BMJ)* 2021, doi:10.1136/gutjnl-2021-324789.
5. Lacson E, Argyropoulos CP, Manley HJ, Aweh G, Chin AI, Salman LH, Hsu CM, Johnson DS, Weiner DE. Immunogenicity of SARS-CoV-2 Vaccine in Dialysis. *medRxiv* 2021:2021.2004.2008.21254779, doi:10.1101/2021.04.08.21254779.
6. Madhi S, Koen A, Fairlie L, Cutland C, Baillie V, Padayachee S, Dheda K, Barnabas S, Bhorat QE, Briner C, et al. ChAdOx1 nCoV-19 (AZD1222) Vaccine in People Living With and Without HIV. 2021, doi:10.21203/rs.3.rs-322470/v1.
7. Ou MT, Boyarsky BJ, Motter JD, Greenberg RS, Teles AT, Ruddy JA, Krach MR, Jain VS, Werbel WA, Avery RK, et al. Safety and Reactogenicity of 2 Doses of SARS-CoV-2 Vaccination in Solid Organ Transplant Recipients. *Transplantation* 2021, doi:10.1097/TP.0000000000003780.
8. Wong S-Y, Dixon R, Pazos VM, Gnjatic S, Colombel J-F, Cadwell K, Group I-IW. Serological response to mRNA COVID-19 vaccines in IBD patients receiving biological therapies. *Gastroenterology* 2021, doi:10.1053/j.gastro.2021.04.025.
9. Scurr MJ, Zelek WM, Lippiatt G, Somerville M, Burnell SEA, Capitani L, Davies K, Lawton H, Tozer T, Rees T, et al. Whole blood-based measurement of SARS-CoV-2-specific T cell responses reveals asymptomatic infection and vaccine efficacy in healthy subjects and patients with solid organ cancers. *medRxiv* 2021:2021.2006.2002.21258218, doi:10.1101/2021.06.02.21258218.
10. Nadesalingam A, Cantoni D, Wells DA, Aguinam ET, Ferrari M, Smith P, Chan A, Carnell G, Ohlendorf L, Einhauser S, et al. Breadth of neutralising antibody responses to SARS-CoV-2 variants of concern is augmented by vaccination following prior infection: studies in UK healthcare workers and immunodeficient patients. *medRxiv* 2021:2021.2006.2003.21257901, doi:10.1101/2021.06.03.21257901.
11. Miele M, Busà R, Russelli G, Sorrentino MC, Bella MD, Timoneri F, Mularoni A, Panarello G, Vitulo P, Conaldi PG, et al. Impaired anti-SARS-CoV-2 Humoral and Cellular Immune Response induced by Pfizer-BioNTech BNT162b2 mRNA Vaccine in Solid Organ Transplanted Patients. *American Journal of Transplantation* 2021, n/a, doi:https://doi.org/10.1111/ajt.16702.
12. Cucchiari D, Egri N, Bodro M, Herrera S, Risco-Zevallos JD, Casals-Urquiza J, Cofan F, Moreno A, Rovira J, Banon-Maneus E, et al. Cellular and humoral response after mRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients. *American Journal of Transplantation* 2021, n/a, doi:https://doi.org/10.1111/ajt.16701.
13. Ruddy JA, Connolly CM, Boyarsky BJ, Werbel WA, Christopher-Stine L, Garonzik-Wang J, Segev DL, Paik JJ. High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases. *Annals of the Rheumatic Diseases* 2021, doi:10.1136/annrheumdis-2021-220656.
14. Chan L, Fuca N, Zeldis E, Campbell K, Shaikh A. Antibody Response to mRNA-1273 SARS-CoV-2 Vaccine in Hemodialysis Patients with and without Prior COVID-19. *Clinical Journal of the American Society of Nephrology* 2021, doi:10.2215/CJN.04080321.
15. Husain SA, Tsapepas D, Paget KF, Chang J-H, Crew RJ, Dube GK, Fernandez HE, Morris HK, Mohan S, Cohen DJ. Post-vaccine anti-SARS-CoV-2 spike protein antibody development in kidney transplants recipients. *Kidney International Reports* 2021, doi:10.1016/j.ekir.2021.04.017.
16. Thakkar A, Lugo JG, Goradia N, Gali R, Shapiro LC, Pradhan K, Rahman S, Kim SY, Ko B, Sica RA, et al. Seroconversion rates following COVID-19 vaccination amongst patients with malignant disease- the impact of diagnosis and cancer-directed therapies. *medRxiv* 2021:2021.2005.2007.21256824, doi:10.1101/2021.05.07.21256824.
17. Schmidt T, Klemis V, Schub D, Schneitler S, Reichert MC, Wilkens H, Sester U, Sester M, Mihm J. Cellular immunity predominates over humoral immunity after the first dose of COVID-19 vaccines in solid organ transplant recipients. *medRxiv* 2021:2021.2005.2007.21256809, doi:10.1101/2021.05.07.21256809.
18. Al-Janabi A, Littlewood Z, Griffiths CEM, Hunter HJA, Chinoy H, Moriarty C, Yiu ZZN, Warren RB. Antibody responses to single-dose SARS-CoV-2 vaccination in patients receiving immunomodulators for immune-mediated inflammatory disease. *British Journal of Dermatology* 2021, n/a, doi:https://doi.org/10.1111/bjd.20479.

19. Anand S, Montez-Rath ME, Han J, Garcia P, Cadden L, Hunsader P, Kerschmann R, Beyer P, Dittrich M, Block GA, et al. Antibody Response to COVID-19 vaccination in Patients Receiving Dialysis. *medRxiv* 2021:2021.2005.2006.21256768, doi:10.1101/2021.05.06.21256768.
20. Ben-Dov IZ, Oster Y, Tzukert K, Alster T, Bader R, Israeli R, Asayag H, Aharon M, Burstein I, Pri-Chen H, et al. The 5-months impact of tozinameran (BNT162b2) mRNA vaccine on kidney transplant and chronic dialysis patients. *medRxiv* 2021:2021.2006.2012.21258813, doi:10.1101/2021.06.12.21258813.
21. Broseta JJ, Rodríguez-Espinosa D, Rodríguez N, Mosquera MDM, Marcos MÁ, Egri N, Pascal M, Soruco E, Bedini JL, Bayés B, et al. Humoral and Cellular Responses to mRNA-1273 and BNT162b2 SARS-CoV-2 Vaccines Administered to Hemodialysis Patients. *Am J Kidney Dis* 2021, 2021/06/27, doi:10.1053/j.ajkd.2021.06.002.
22. Palich R, Veyri M, Vozy A, Marot S, Gligorov J, Benderra MA, Maingon P, Morand-Joubert L, Adjoutah Z, Marcelin AG, et al. High seroconversion rate but low antibody titers after two injections of BNT162b2 (Pfizer-BioNTech) vaccine in patients treated by chemotherapy for solid cancers. *Ann Oncol* 2021, 2021/06/26, doi:10.1016/j.annonc.2021.06.018.
23. Achiron A, Mandel M, Dreyer-Alster S, Harari G, Magalashvili D, Sonis P, Dolev M, Menascu S, Flechter S, Falb R, et al. Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. *Therapeutic Advances in Neurological Disorders* 2021, 14:17562864211012835, doi:10.1177/17562864211012835.
24. Addeo A, Shah PK, Bordry N, Hudson RD, Albracht B, Di Marco M, Kaklamani V, Dietrich P-Y, Taylor BS, Simand P-F, et al. Immunogenicity of SARS-CoV-2 messenger RNA Vaccines in Patients with Cancer. *Cancer Cell* 2021:S1535610821003305, doi:10.1016/j.ccell.2021.06.009.
25. Agha M, Blake M, Chilleo C, Wells A, Haidar G. Suboptimal response to COVID-19 mRNA vaccines in hematologic malignancies patients. *medRxiv* 2021:2021.2004.2006.21254949, doi:10.1101/2021.04.06.21254949.
26. Agur T, Ben-Dor N, Goldman S, Lichtenberg S, Herman-Edelstein M, Yahav D, Rozen-Zvi B, Zingerman B. Antibody response to mRNA SARS-CoV-2 vaccine among dialysis patients - a prospective cohort study. *Nephrology Dialysis Transplantation* 2021, doi:10.1093/ndt/gfab155.
27. Apostolidis SA, Kakara M, Painter MM, Goel RR, Mathew D, Lenzi K, Rezk A, Patterson KR, Espinoza DA, Kadri JC, et al. Altered cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. *medRxiv* 2021:2021.2006.2023.21259389, doi:10.1101/2021.06.23.21259389
- 10.1101/2021.06.23.21259389
28. Barda N, Dagan N, Balicer RD. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. Reply. *The New England Journal of Medicine* 2021, 384, doi:10.1056/NEJMc2104281.
29. Barrière J, Chamorey E, Adjoutah Z, Castelnaud O, Mahamat A, Marco S, Petit E, Leysalle A, Raimondi V, Carles M. Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors. *Annals of Oncology: Official Journal of the European Society for Medical Oncology* 2021, doi:10.1016/j.annonc.2021.04.019.
30. Benotmane I, Gautier-Varga G, Cognard N, Olagne J, Heibel F, Braun-Parvez L, Martzloff J, Perrin P, Moulin B, Fafi-Kremer S, et al. Weak anti-Severe Acute Respiratory Syndrome Coronavirus 2 antibody response after the first injection of an mRNA Coronavirus Disease 2019 vaccine in kidney transplant recipients. *Kidney International* 2021, doi:10.1016/j.kint.2021.03.014.
31. Benotmane I, Gautier-Vargas G, Cognard N, Olagne J, Heibel F, Braun-Parvez L, Martzloff J, Perrin P, Moulin B, Fafi-Kremer S, et al. Low immunization rates among kidney transplant recipients who received two doses of the mRNA-1273 SARS-CoV-2 vaccine. *Kidney International* 2021, doi:10.1016/j.kint.2021.04.005.
32. Bertrand D, Hamzaoui M, Lemée V, Lamulle J, Hanoy M, Laurent C, Lebourg L, Etienne I, Lemoine M, Roy FL, et al. Antibody and T Cell Response to SARS-CoV-2 Messenger RNA BNT162b2 Vaccine in Kidney Transplant Recipients and Hemodialysis Patients. *Journal of the American Society of Nephrology* 2021, doi:10.1681/ASN.2021040480.
33. Bigaut K, Kremer L, Fleury M, Lanotte L, Collongues N, e Seze J. Impact of disease-modifying treatments on humoral response after COVID-19 vaccination: A mirror of the response after SARS-CoV-2 infection. *Revue neurologique* 2021, doi:10.1016/j.neurol.2021.05.001.
34. Bird S, Panopoulou A, Shea RL, Tsui M, Saso R, Sud A, West S, Barwood J, Kaczmarek E, Panlaqui C, et al. Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma. *The Lancet Haematology* 2021, doi:10.1016/S2352-3026(21)00110-1.
35. Boekel L, Steenhuis M, Hooijberg F, Besten Y, van Kempen Z, Kummer L, van Dam K, Stalman E, Vogelzang E, Christianawati O, et al. Antibody Development after SARS-CoV-2 Vaccinations in Elderly Patients with Autoimmune Diseases: Data From a Prospective Controlled Cohort Study. *SSRN- Lancet prepublication* 2021.
36. Botwin GJ, Li D, Figueiredo J, Cheng S, Braun J, McGovern DPB, Melmed GY. Adverse Events After SARS-CoV-2 mRNA Vaccination Among Patients With Inflammatory Bowel Disease. *American Journal of Gastroenterology* 2021, Publish Ahead of Print, doi:10.14309/ajg.0000000000001342.
37. Braun-Moscovici Y, Kaplan M, Braun M, Markovits D, Giryas S, Toledano K, Tavor Y, Dolnikov K, Balbir-Gurman A. Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2. *Annals of the Rheumatic Diseases* 2021, doi:10.1136/annrheumdis-2021-220503.

38. Chavarot N, Ouedrani A, Marion O, Leruez-Ville M, Villain E, Baaziz M, Del Bello A, Burger C, Sberro-Soussan R, Martinez F, et al. Poor Anti-SARS-CoV-2 Humoral and T-cell Responses After 2 Injections of mRNA Vaccine in Kidney Transplant Recipients Treated with Belatacept. *Transplantation* 2021, doi:10.1097/TP.0000000000003784.
39. Chodick G, Tene L, Rotem RS, Patalon T, Gazit S, Ben-Tov A, Weil C, Goldshtein I, Twig G, Cohen D, et al. The effectiveness of the TWO-DOSE BNT162b2 vaccine: analysis of real-world data. *Clinical Infectious Diseases* 2021, doi:10.1093/cid/ciab438.
40. Cohen D, Hazut Krauthammer S, Cohen YC, Perry C, Avivi I, Herishanu Y, Even-Sapir E. Correlation between BNT162b2 mRNA Covid-19 vaccine-associated hypermetabolic lymphadenopathy and humoral immunity in patients with hematologic malignancy. *European Journal of Nuclear Medicine and Molecular Imaging* 2021, doi:10.1007/s00259-021-05389-x.
41. Danthu C, Hantz S, Dahlem A, Duval M, Ba B, Guibbert M, Ouafi ZE, Ponsard S, Berrahal I, Achard JM, et al. Humoral Response after SARS-Cov-2 mRNA Vaccine in a Cohort of Hemodialysis Patients and Kidney Transplant Recipients. *Journal of the American Society of Nephrology* 2021, doi:10.1681/ASN.2021040490.
42. Deepak P, Kim W, Paley MA, Yang M, Carvidi AB, El-Qunni AA, Haile A, Huang K, Kinnett B, Liebeskind MJ, et al. Glucocorticoids and B Cell Depleting Agents Substantially Impair Immunogenicity of mRNA Vaccines to SARS-CoV-2. *medRxiv* 2021:2021.2004.2005.21254656, doi:10.1101/2021.04.05.21254656.
43. Diefenbach C, Caro J, Koide A, Grossbard M, Goldberg JD, Raphael B, Hymes K, Moskovits T, Kreditor M, Kaminetzky D, et al. Impaired Humoral Immunity to SARS-CoV-2 Vaccination in Non-Hodgkin Lymphoma and CLL Patients. *medRxiv* 2021:2021.2006.2002.21257804, doi:10.1101/2021.06.02.21257804.
44. Duarte R, Roldão M, Figueiredo C, Ferrer F, Gonçalves H, Luz I, Sofia F, Lopes K. Humoral Response to BNT162b2 mRNA Covid19 Vaccine in Peritoneal and Hemodialysis Patients: a Comparative Study. *medRxiv* 2021:2021.2006.2014.21258113, doi:10.1101/2021.06.14.21258113.
45. Ducloux D, Colladant M, Chabannes M, Yannaraki M, Courivaud C. Humoral response after three doses of BNT162b2 mRNA COVID-19 vaccine in patients on hemodialysis. *Kidney Int* 2021, 2021/07/04, doi:10.1016/j.kint.2021.06.025.
46. Salinas AF, Mortari EP, Terreri S, Quintarelli C, Pulvirenti F, Cecca SD, Guercio M, Milito C, Bonanni L, Auria S, et al. SARS-CoV-2 Vaccine Induced Atypical Immune Responses in Antibody Defects: everybody does their best. *medRxiv* 2021:2021.2006.2024.21259130, doi:10.1101/2021.06.24.21259130.
47. Firket L, Descy J, Seidel L, Bonvoisin C, Bouquegneau A, Grosch S, Jouret F, Weekers L. Serological response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients depends on prior exposure to SARS-CoV-2. *American Journal of Transplantation* 2021, n/a, doi:https://doi.org/10.1111/ajt.16726.
48. Frantzen L, Cavaille G, Thibeaut S, El-Haik Y. Efficacy of the BNT162b2 mRNA Covid-19 Vaccine in a hemodialysis cohort. *Nephrology, Dialysis, Transplantation: Official Publication of the European Dialysis and Transplant Association - European Renal Association* 2021, doi:10.1093/ndt/gfab165.
49. Frater J, Ewer KJ, Ogbe A, Pace M, Adele S, Adland E, Alagaratnam J, Aley PK, Ali M, Ansari MA, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial. *The Lancet HIV* 2021:S235230182100103X, doi:10.1016/S2352-3018(21)00103-X.
50. Furer V, Eviatar T, Zisman D, Peleg H, Paran D, Levartovsky D, Zisapel M, Elalouf O, Kaufman I, Meidan R, et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. *Annals of the Rheumatic Diseases* 2021, doi:10.1136/annrheumdis-2021-220647.
51. Geisen UM, Berner DK, Tran F, Sümbül M, Vullriede L, Ciripoi M, Reid HM, Schaffarzyk A, Longardt AC, Franzenburg J, et al. Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort. *Annals of the Rheumatic Diseases* 2021, doi:10.1136/annrheumdis-2021-220272.
52. Ghione P, Gu JJ, Attwood K, Torka P, Goel S, Sundaram S, Mavis C, Johnson M, Thomas R, McWhite KM, et al. Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell directed therapies. *Blood* 2021, 2021/07/01, doi:10.1182/blood.2021012443.
53. Goupil R, Benlarbi M, Beaubien-Souigny W, Nadeau-Fredette A-C, Chatterjee D, Goyette G, Gunaratnam L, Lamarche C, Tom A, Finzi A, et al. Short-term antibody response after 1 dose of BNT162b2 vaccine in patients receiving hemodialysis. *CMAJ* 2021, doi:10.1503/cmaj.210673.
54. Grupper A, Rabinowich L, Schwartz D, Schwartz IF, Ben-Yehoyada M, Shashar M, Katchman E, Halperin T, Turner D, Goykhman Y, et al. Reduced humoral response to mRNA SARS-Cov-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus. *American Journal of Transplantation* 2021, n/a, doi:https://doi.org/10.1111/ajt.16615.
55. Grupper A, Sharon N, Finn T, Cohen R, Israel M, Agbaria A, Rechavi Y, Schwartz IF, Schwartz D, Lellouch Y, et al. Humoral Response to the Pfizer BNT162b2 Vaccine in Patients Undergoing Maintenance Hemodialysis. *Clinical Journal of the American Society of Nephrology* 2021, doi:10.2215/CJN.03500321.
56. Guerrieri S, S L, C Z, A N, M F, L M. Serological response to SARS-CoV-2 vaccination in multiple sclerosis patients treated with fingolimod or ocrelizumab: an initial real-life experience. *J Neurol* 2021, 2021/07/01:1-5, doi:10.1007/s00415-021-10663-x.

57. Haberman RH, Herati RS, Simon D, Samanovic M, Blank RB, Tuen M, Koralov SB, Atreya R, Tascilar K, Allen JR, et al. Methotrexate Hampers Immunogenicity to BNT162b2 mRNA COVID-19 Vaccine in Immune-Mediated Inflammatory Disease. *medRxiv* 2021:2021.2005.2011.21256917, doi:10.1101/2021.05.11.21256917.
58. Hadi YB, Thakkar S, Shah-Khan SM, Hutson W, Sarwari A, Singh S. COVID-19 vaccination is safe and effective in patients with inflammatory bowel disease: Analysis of a large multi-institutional research network in United States. *Gastroenterology* 2021, doi:10.1053/j.gastro.2021.06.014.
59. Hagin D, Freund T, Navon M, Halperin T, Adir D, Marom R, Levi I, Benor S, Alcalay Y, Freund NT. Immunogenicity of Pfizer-BioNTech COVID-19 Vaccine in Patients with Inborn Errors of Immunity. *The Journal of Allergy and Clinical Immunology* 2021, doi:10.1016/j.jaci.2021.05.029.
60. Haidar G, Agha M, Lukanski A, Linstrum K, Troyan R, Bilderback A, Rothenberger S, McMahon DK, Crandall M, Enick PN, et al. Immunogenicity of COVID-19 Vaccination in Immunocompromised Patients: An Observational, Prospective Cohort Study Interim Analysis. *medRxiv* 2021:2021.2006.2028.21259576, doi:10.1101/2021.06.28.21259576.
61. Harrington P, Lavallade Hd, Doores K, O'Reilly A, Seow J, Graham C, Lechmere T, Radia D, Dillon R, Shanmugaraj Y, et al. Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms. *medRxiv* 2021:2021.2004.2027.21256096, doi:10.1101/2021.04.27.21256096.
62. Harrington P, Doores KJ, Radia D, O'Reilly A, Lam HPJ, Seow J, Graham C, Lechmere T, McLornan D, Dillon R, et al. Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukaemia. *British Journal of Haematology* 2021, n/a, doi:https://doi.org/10.1111/bjh.17568.
63. Havlin J, Svorcova M, Dvorackova E, Lastovicka J, Lischke R, Kalina T, Hubacek P. Immunogenicity of BNT162b2 mRNA COVID-19 vaccine and SARS-CoV-2 infection in lung transplant recipients. *The Journal of Heart and Lung Transplantation: The Official Publication of the International Society for Heart Transplantation* 2021, doi:10.1016/j.healun.2021.05.004.
64. Herishanu Y, Avivi I, Aharon A, Shefer G, Levi S, Bronstein Y, Morales Moshishvili M, Ziv-Baran T, Shorer Y, Scarfo L, et al. Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia. *Blood* 2021, doi:10.1182/blood.2021011568.
65. Itzhaki Ben Zadok O, Shaul AA, Ben- Avraham B, Yaari V, Zvi HB, Shostak Y, Pertzov B, Eliakim- Raz N, Abed G, Abuhazira M, et al. Immunogenicity of the BNT162b2 mRNA Vaccine in Heart Transplanted Patients-A Prospective Cohort Study. *European Journal of Heart Failure* 2021, n/a, doi:https://doi.org/10.1002/ejhf.2199.
66. Jahn M, Korth J, Dorsch O, Anastasiou OE, Sorge-Hädicke B, Tyczynski B, Gäckler A, Witzke O, Dittmer U, Doff S, et al. Humoral Response to SARS-CoV-2-Vaccination with BNT162b2 (Pfizer-BioNTech) in Patients on Hemodialysis. *Vaccines* 2021, 9:360, doi:10.3390/vaccines9040360.
67. Kamar N, Abravanel F, Marion O, Couat C, Izopet J, Bello AD. Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients. *New England Journal of Medicine* 2021, doi:10.1056/NEJMc2108861.
68. Korth J, Jahn M, Dorsch O, Anastasiou OE, Sorge-Hädicke B, Eisenberger U, Gäckler A, Dittmer U, Witzke O, Wilde B, et al. Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech). *Viruses* 2021, 13:756, doi:10.3390/v13050756.
69. Lesny P, Anderson M, Cloherty G, Stec M, Haase-Fielitz A, Haarhaus M, Santos C, Lucas C, Macario F, Haase M. Immunogenicity of a first dose of mRNA- or vector-based SARS-CoV-2 vaccination in dialysis patients: a multicenter prospective observational pilot study. *Journal of Nephrology* 2021, doi:10.1007/s40620-021-01076-0.
70. Levy I, Wieder-Finesod A, Litchevski V, Biber A, Indenbaum V, Olmer L, Huppert A, Mor O, Goldstein M, Sapir E, et al. Immunogenicity and Safety of the BNT162b2 mRNA COVID-19 Vaccine in People Living with HIV-1. *SSRN Preprint* 2021.
71. Longlune N, Nogier MB, Miedougé M, Gabilan C, Cartou C, Seigneuric B, Del Bello A, Marion O, Faguer S, Izopet J, et al. High immunogenicity of a messenger RNA based vaccine against SARS-CoV-2 in chronic dialysis patients. *Nephrology Dialysis Transplantation* 2021, doi:10.1093/ndt/gfab193.
72. Maneikis K, Šablauskas K, Ringelevičiūtė U, Vaitekėnaitė V, Čekauskienė R, Kryžauskaitė L, Naumovas D, Banys V, Pečeliūnas V, Beinortas T, et al. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study. *The Lancet Haematology - Preprint on May 6 2021*, 0, doi:10.1016/S2352-3026(21)00169-1.
73. Marinaki S, Adamopoulos S, Degiannis D, Roussos S, Pavlopoulou ID, Hatzakis A, Boletis IN. Immunogenicity of SARS-CoV-2 BNT162b2 vaccine in solid organ transplant recipients. *American Journal of Transplantation* 2021, n/a, doi:https://doi.org/10.1111/ajt.16607.
74. Marion O, Del Bello A, Abravanel F, Couat C, Faguer S, Esposito L, Hebral AL, Izopet J, Kamar N. Safety and Immunogenicity of Anti-SARS-CoV-2 Messenger RNA Vaccines in Recipients of Solid Organ Transplants. *Annals of Internal Medicine* 2021, doi:10.7326/M21-1341.
75. Massarweh A, Eliakim-Raz N, Stemmer A, Levy-Barda A, Yust-Katz S, Zer A, Benouaich-Amiel A, Ben-Zvi H, Moskovits N, Brenner B, et al. Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer. *JAMA oncology* 2021, doi:10.1001/jamaoncol.2021.2155.

76. Mazzola A, Todesco E, Drouin S, Hazan F, Marot S, Thabut D, Varnous S, Soulié C, Barrou B, Marcelin A-G, et al. Poor Antibody Response after Two Doses of SARS-CoV-2 vaccine in Transplant Recipients. *Clinical Infectious Diseases* 2021, doi:10.1093/cid/ciab580.
77. Monin L, Laing AG, Muñoz-Ruiz M, McKenzie DR, Barrio IdMd, Alaguthurai T, Domingo-Vila C, Hayday TS, Graham C, Seow J, et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. *The Lancet Oncology* 2021, 0, doi:10.1016/S1470-2045(21)00213-8.
78. Monzó JJB, Rodríguez-Espinosa D, Soruco E, Maduell F. Weekly seroconversion rate of the mRNA-1273 SARS-CoV-2 vaccine in hemodialysis patients. *Nephrology Dialysis Transplantation* 2021, doi:10.1093/ndt/gfab195.
79. Nadesalingam A, Cantoni D, Wells DA, Aguinam ET, Ferrari M, Smith P, Chan A, Carnell G, Ohlendorf L, Einhauser S, et al. Paucity and discordance of neutralising antibody responses to SARS-CoV-2 VOCs in vaccinated immunodeficient patients and health-care workers in the UK. *The Lancet Microbe* 2021, doi:10.1016/S2666-5247(21)00157-9.
80. Narasimhan M, Mahimainathan L, Clark AE, Usmani A, Cao J, Araj E, Torres F, Sarode R, Kaza V, Lacelle C, et al. Serological Response in Lung Transplant Recipients after Two Doses of SARS-CoV-2 mRNA Vaccines. *Vaccines (Basel)* Please note: Preprint on May 6 2021, 9,2021/07/03, doi:10.3390/vaccines9070708.
81. Nikolina B-J. Clinical consequences of the suboptimal effect of messenger RNA (mRNA)-based SARS-CoV-2 vaccine in renal transplant recipients. *Therapeutic Apheresis and Dialysis* 2021, n/a, doi:https://doi.org/10.1111/1744-9987.13695.
82. Oekelen OV, Gleason CR, Agte S, Srivastava K, Beach K, Aleman A, Kappes K, Mouhieddine TH, Wang B, Chari A, et al. Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma. *Cancer Cell* 2021, 0, doi:10.1016/j.ccell.2021.06.014
10.1016/j.ccell.2021.06.014</p>
83. Parry HM, McIlroy G, Bruton R, Ali M, Stephens C, Damery S, Otter A, McSkeane T, Rolfe H, Faustini S, et al. Antibody Responses After First and Second COVID-19 Vaccination in Patients With Chronic Lymphocytic Leukaemia. *SSRN Preprints* 2021.
84. Peled Y, Ram E, Lavee J, Sternik L, Segev A, Wieder-Finesod A, Mandelboim M, Indenbaum V, Levy I, Raanani E, et al. BNT162b2 vaccination in heart transplant recipients: Clinical experience and antibody response. *The Journal of Heart and Lung Transplantation: The Official Publication of the International Society for Heart Transplantation* 2021, doi:10.1016/j.healun.2021.04.003.
85. Pimpinelli F, Marchesi F, Piaggio G, Giannarelli D, Papa E, Falcucci P, Pontone M, Di Martino S, Laquintana V, La Malfa A, et al. Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution. *Journal of Hematology & Oncology* 2021, 14:81, doi:10.1186/s13045-021-01090-6.
86. Rabinowich L, Grupper A, Baruch R, Ben-Yehoyada M, Halperin T, Turner D, Katchman E, Levi S, Houry I, Lubezky N, et al. Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients. *Journal of Hepatology* 2021, doi:10.1016/j.jhep.2021.04.020.
87. Ram R, Hagin D, Kikozashvili N, Freund T, Amit O, Bar-On Y, Beyar-Katz O, Shefer G, Moshiahvili MM, Karni C, et al. Safety and Immunogenicity of the BNT162b2 mRNA Covid-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy - a Single Center Prospective Cohort Study. *Transplant Cell Ther* 2021, 2021/07/03, doi:10.1016/j.jtct.2021.06.024.
88. Rincon-Arevalo H, Choi M, Stefanski A-L, Halleck F, Weber U, Szelinski F, Jahrsdörfer B, Schrezenmeier H, Ludwig C, Sattler A, et al. Impaired antigen-specific memory B cell and plasma cell responses including lack of specific IgG upon SARS-CoV-2 BNT162b2 vaccination among Kidney Transplant and Dialysis patients. *medRxiv* 2021:2021.2004.2015.21255550, doi:10.1101/2021.04.15.21255550.
89. Rodríguez-Espinosa D, Broseta JJ, Francisco M, José Luis B, Vera M. Humoral response of mRNA-1273 SARS-CoV-2 vaccine in peritoneal dialysis patients. *Kidney International* 2021:S0085253821005585, doi:10.1016/j.kint.2021.05.018.
90. Roeker LE, Knorr DA, Thompson MC, Nivar M, Lebowitz S, Peters N, Deonaraine I, Momotaj S, Sharan S, Chanlatte V, et al. COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia. *Leukemia* 2021:1-3, doi:10.1038/s41375-021-01270-w.
91. Rozen-Zvi B, et al. Antibody response to mRNA SARS-CoV-2 vaccine among kidney transplant recipients – Prospective cohort study. *Clinical Microbiology and Infection* 2021, doi:10.1016/j.cmi.2021.04.028.
92. Rubbert-Roth A, Vuilleumier N, Ludewig B, Schmiedeberg K, Haller C, Kempis Jv. Anti-SARS-CoV-2 mRNA vaccine in patients with rheumatoid arthritis. *The Lancet Rheumatology* 2021, 0, doi:10.1016/S2665-9913(21)00186-7.
93. Ruddy JA, Boyarsky BJ, Werbel WA, Bailey JR, Karaba AH, Garonzik-Wang JM, Segev DL, Durand CM. Safety and antibody response to the first dose of SARS-CoV-2 messenger RNA vaccine in persons with HIV. *AIDS (London, England)* 2021, doi:10.1097/QAD.0000000000002945.
94. Sattler A, Schrezenmeier E, Weber UA, Potekhin A, Bachmann F, Straub-Hohenbleicher H, Budde K, Storz E, Proß V, Bergmann Y, et al. Impaired humoral and cellular immunity after SARS-CoV2 BNT162b2 (Tozinameran) prime-boost vaccination in kidney transplant recipients. *The Journal of Clinical Investigation* 2021, doi:10.1172/JCI150175.

95. Schrezenmeier E, Bergfeld L, Hillus D, Lippert J-D, Weber U, Tober-Lau P, Landgraf I, Schwarz T, Kappert K, Stefanski A-L, et al. Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis. *medRxiv* 2021:2021.2003.2031.21254683, doi:10.1101/2021.03.31.21254683.
96. Shostak Y, Shafran N, Heching M, Rosengarten D, Shtraichman O, Shitenberg D, Amor SM, Yahav D, Zvi HB, Pertzov B, et al. Early humoral response among lung transplant recipients vaccinated with BNT162b2 vaccine. *The Lancet Respiratory Medicine* 2021, doi:10.1016/S2213-2600(21)00184-3.
97. Shroff RT, Chalasani P, Wei R, Pennington D, Quirk G, Schoenle MV, Uhrlaub JL, Ripperger TJ, Jergović M, Dalgai S, et al. Immune Responses to COVID-19 mRNA Vaccines in Patients with Solid Tumors on Active, Immunosuppressive Cancer Therapy. *medRxiv* 2021:2021.2005.2013.21257129, doi:10.1101/2021.05.13.21257129.
98. Shrotri M, Fragaszy E, Geismar C, Nguyen V, Beale S, Braithwaite I, Byrne TE, Erica Fong WL, Kovar J, Navaratnam AMD, et al. Spike-antibody responses following first and second doses of ChAdOx1 and BNT162b2 vaccines by age, gender, and clinical factors - a prospective community cohort study (Virus Watch). *medRxiv* 2021:2021.2005.2012.21257102, doi:10.1101/2021.05.12.21257102.
99. Simon B, Rubey H, Treipl A, Gromann M, Hemedi B, Zehetmayer S, Kirsch B. Hemodialysis Patients Show a Highly Diminished Antibody Response after COVID-19 mRNA Vaccination Compared to Healthy Controls. *medRxiv* 2021:2021.2003.2026.21254259, doi:10.1101/2021.03.26.21254259.
100. Simon D, Tascilar K, Fagni F, Krönke G, Kleyer A, Meder C, Atreya R, Leppkes M, Kremer AE, Ramming A, et al. SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases. *Annals of the Rheumatic Diseases* 2021, doi:10.1136/annrheumdis-2021-220461.
101. Spiera R, Jinich S, Jannat-Khah D. Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS-CoV-2 vaccination in patients with rheumatic diseases. *Annals of the Rheumatic Diseases* 2021, doi:10.1136/annrheumdis-2021-220604.
102. Strengert M, Becker M, Ramos GM, Dulovic A, Gruber J, Juengling J, Lürken K, Beigel A, Wrenger E, Lonnemann G, et al. Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on hemodialysis. *medRxiv* 2021:2021.2005.2026.21257860, doi:10.1101/2021.05.26.21257860.
103. Terpos E, Trougakos IP, Gavriatopoulou M, Papassotiriou I, Sklirou AD, Ntanasis-Stathopoulos I, Papanagnou E-DD, Fotiou D, Kastritis E, Dimopoulos MA. Low Neutralizing Antibody Responses Against SARS-CoV-2 in Elderly Myeloma Patients After the First BNT162b2 Vaccine Dose. *Blood* 2021, doi:10.1182/blood.2021011904.
104. Terpos E, Zagouri F, Lontos M, Sklirou AD, Koutsoukos K, Markellos C, Briasoulis A, Papanagnou E-D, Trougakos IP, Dimopoulos M-A. Low titers of SARS-CoV-2 neutralizing antibodies after first vaccination dose in cancer patients receiving checkpoint inhibitors. *Journal of Hematology & Oncology* 2021, 14:86, doi:10.1186/s13045-021-01099-x.
105. Torreggiani M, Bianchi S, Fois A, Fessi H, Piccoli GB. Neutralizing SARS-CoV-2 antibody response in dialysis patients after the first dose of the BNT162b2 mRNA Covid-19 vaccine. The war is far from being won. *Kidney International* 2021, doi:10.1016/j.kint.2021.04.010.
106. Tzarfati KH, Gutwein O, Apel A, Rahimi-Levene N, Sadovnik M, Harel L, Benveniste-Levkovitz P, Chaim AB, Koren-Michowitz M. BNT162b2 COVID-19 Vaccine is significantly less effective in patients with hematologic malignancies. *Am J Hematol* 2021, 2021/06/30, doi:10.1002/ajh.26284
107. Waissengrin B, Agbarya A, Safadi E, Padova H, Wolf I. Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors. *The Lancet Oncology* 2021, 0, doi:10.1016/S1470-2045(21)00155-8.
108. Werbel WA, Boyarsky BJ, Ou MT, Massie AB, Tobian AAR, Garonzik-Wang JM, Segev DL. Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series. *Annals of Internal Medicine* 2021.
109. Yanay NB, Freiman S, Shapira Ma, Wishahi S, Hamze M, Elhaj M, Zaher M, Armaly Z. Experience with SARS-COV-2 BNT162b2 mRNA vaccine in dialysis patients. *Kidney International* 2021, doi:10.1016/j.kint.2021.04.006.
110. Yau K, Abe KT, Naimark D, Oliver MJ, Perl J, Leis JA, Bolotin S, Tran V, Mullin S, Shadowitz E, et al. The Humoral Response to the BNT162b2 Vaccine in Hemodialysis Patients. *medRxiv* 2021:2021.2005.2024.21257425, doi:10.1101/2021.05.24.21257425.
111. Yi SG, Knight RJ, Graviss EA, Nguyen DT, Ghobrial RM, Gaber AO, Huang HJ. Kidney Transplant Recipients Rarely Show an Early Antibody Response Following the First COVID-19 Vaccine Administration. *Transplantation* 2021, doi:10.1097/TP.0000000000003764.
112. Young-Xu Y, Korves C, Powell EI, Zwain GM, Smith J. Coverage and effectiveness of mRNA SARS-CoV-2 vaccines among United States Veterans. *medRxiv* 2021:2021.2006.2014.21258906, doi:10.1101/2021.06.14.21258906.
113. Chevallier P, Coste- Burel M, Le Bourgeois A, Peterlin P, Garnier A, Béné MC, Imbert BM, Drumel T, Le Gouill S, Moreau P, et al. Safety and immunogenicity of a first dose of SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic stem- cells recipients. *eJHaem* 2021:jha2.242, doi:10.1002/jha2.242.
114. Espi M, Charmetant X, Barba T, Pelletier C, Koppe L, Chalencou E, Kalbacher E, Mathias V, Ovize A, Cart-Tanneur E, et al. Justification, safety, and efficacy of a third dose of mRNA vaccine in maintenance hemodialysis patients: a prospective observational study. *medRxiv* 2021:2021.2007.2002.21259913, doi:10.1101/2021.07.02.21259913.

115. Tenforde MW, Patel MM, Ginde AA, Douin DJ, Talbot HK, Casey JD, Mohr NM, Zepeski A, Gaglani M, McNeal T, et al. Effectiveness of SARS-CoV-2 mRNA Vaccines for Preventing Covid-19 Hospitalizations in the United States. *medRxiv* 2021:2021.2007.2008.21259776, doi:10.1101/2021.07.08.21259776.
116. Moyon Q, Sterlin D, Miyara M, Anna F, Mathian A, Lhote R, Ghillani-Dalbin P, Breillat P, Mudumba S, de Alba S, et al. BNT162b2 vaccine-induced humoral and cellular responses against SARS-CoV-2 variants in Systemic Lupus Erythematosus. *medRxiv* 2021:2021.2007.2007.21260124, doi:10.1101/2021.07.07.21260124.
117. Mahil SK, Bechman K, Raharja A, Domingo-Vila C, Baudry D, Brown MA, Cope AP, Dasandi T, Graham C, Lechmere T, et al. The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study. *The Lancet Rheumatology* 2021, doi:10.1016/S2665-9913(21)00212-5.
118. Holden IK, Bistrup C, Nilsson AC, Hansen JF, Abazi R, Davidsen JR, Poulsen MK, Lindvig SO, Justesen US, Johansen IS. Immunogenicity of SARS-CoV-2 mRNA vaccine in solid organ transplant recipients. *J Intern Med* 2021, 2021/07/09, doi:10.1111/joim.13361.
119. Goshen-Lago T, Waldhorn I, Holland R, Szwarcwort-Cohen M, Reiner-Benaim A, Shachor-Meyouhas Y, Hussein K, Fahoum L, Baruch M, Peer A, et al. Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer. *JAMA Oncol* 2021, 2021/07/09, doi:10.1001/jamaoncol.2021.2675.
120. Khan N, Mahmud N. Effectiveness of SARS-CoV-2 Vaccination in a Veterans Affairs Cohort of Patients With Inflammatory Bowel Disease With Diverse Exposure to Immunosuppressive Medications. *Gastroenterology* 2021, doi:10.1053/j.gastro.2021.05.044.
121. Iacono D, Cerbone L, Palombi L, Cavalieri E, Sperduti I, Cocchiara RA, Mariani B, Parisi G, Garufi C. Serological response to COVID-19 vaccination in patients with cancer older than 80 years. *Journal of Geriatric Oncology* 2021, doi:10.1016/j.jgo.2021.06.002.
122. Ben-Tov A, Banon T, Chodick G, Kariv R, Assa A, Gazit S. BNT162b2 mRNA COVID-19 Vaccine Effectiveness in Patients with Inflammatory Bowel Disease: Preliminary Real World Data during Mass Vaccination Campaign. *Gastroenterology* 2021, 2021/07/06, doi:10.1053/j.gastro.2021.06.076.
123. Malinis M, Cohen E, Azar MM. Effectiveness of SARS-CoV-2 vaccination in fully vaccinated solid organ transplant recipients. *American Journal of Transplantation* 2021, n/a, doi:https://doi.org/10.1111/ajt.16713.